Sanofi is a leading global biopharmaceutical company that is **R&D-driven and AI-powered**, focused on discovering, developing, and delivering innovative medicines and vaccines to improve people's lives worldwide[1][8]. With a workforce exceeding 100,000 employees across more than 100 countries, Sanofi leverages cutting-edge science and artificial intelligence to address critical healthcare challenges and create sustainable growth[8]. Founded on a heritage of transforming the impossible into the possible, Sanofi's mission centers on chasing scientific breakthroughs and advancing health outcomes in five primary therapeutic areas. The company currently has 82 compounds in clinical development and 24 phase 3 clinical trials, demonstrating a robust and diverse pipeline that spans rare diseases, immunology, neurology, oncology, and vaccines[1][7]. Key achievements include multiple regulatory designations such as orphan and fast track status for novel therapies, and strategic acquisitions to strengthen its pipeline, including Blueprint Medicines (rare diseases/immunology), Dren Bio, Vigil (Alzheimer’s), Vicebio (respiratory vaccines), and others in 2025[3][7]. These moves support Sanofi’s strategy to diversify its portfolio and mitigate risks from patent expirations, such as the anticipated 2031 expiration of Dupixent’s U.S. patent, one of its growth engines[7]. Sanofi is also committed to sustainability and social impact, ranked as the world’s tenth most sustainable company and the top pharmaceutical firm by TIME magazine in 2025[3]. The company announced a major investment plan to spend at least $20 billion in the United States through 2030, emphasizing research, development, and manufacturing expansion to boost innovation, supply chain resilience, and job creation domestically[5]. Under CEO Paul Hudson’s leadership, Sanofi pursues a “play-to-win” strategy, harnessing AI and digital technologies to reshape biopharma manufacturing and accelerate progress against untreated rare diseases[1][6]